Journal: BMC cancer
Article Title: Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing's sarcoma cells.
doi: 10.1186/s12885-025-13691-2
Figure Lengend Snippet: Fig. 6 RNRi and WEE1i cooperate in inducing p53 target gene expression. Cells were exposed to triapine in combination with adavosertib or ZN-c3 for 24 h. CDKN1A and BBC3 expression levels were determined by real-time RT-PCR and normalised to B2M expression levels; relative gene expression levels are the ratio of treated cells to untreated cells. Means ± SEM of each three independent measurements are shown (*p < 0.05, **p < 0.01, ***p < 0.001)
Article Snippet: Twenty-four hours after seeding, cells were treated with triapine (0.125–1 μM; Selleck Chemicals, Planegg, Germany), adavosertib (0.05–0.5 μM; Selleck Chemicals), ZN-c3 (0.3–0.5 μM; Selleck Chemicals), olaparib (0.1–2 μM; Biomol, Hamburg, Germany) and/or veliparib (2.5–20 μM; Biomol) and incubated for 24 h (caspase 3/7 activity, immunoblotting, PCR) or 48 h (flow-cytometric analyses).
Techniques: Targeted Gene Expression, Expressing, Quantitative RT-PCR, Gene Expression